Rare Community Profiles: White Paper Discusses Access Barriers in IgG4-Related Disease (IgG4-RD)
Fotocitizen / Pixabay

Rare Community Profiles: White Paper Discusses Access Barriers in IgG4-Related Disease (IgG4-RD)

  Rare Community Profiles is a Patient Worthy article series of long-form interviews featuring various stakeholders in the rare disease community, such as patients, their families, advocates, scientists, and more.…

Continue Reading Rare Community Profiles: White Paper Discusses Access Barriers in IgG4-Related Disease (IgG4-RD)
ICYMI: Neuraxpharm and Minoryx’s Special Information Film Raises Leukodystrophy Awareness
source: pixabay.com

ICYMI: Neuraxpharm and Minoryx’s Special Information Film Raises Leukodystrophy Awareness

Rare Disease Day may be long past in February, but the fight for rare disease awareness continues. Earlier this year, specialty pharmaceutical company Neuraxpharm Group ("Neuraxpharm") and biotechnology company Minoryx…

Continue Reading ICYMI: Neuraxpharm and Minoryx’s Special Information Film Raises Leukodystrophy Awareness
Physicians Identify Poor Disease Management in Patients with IBD
source: shutterstock.com

Physicians Identify Poor Disease Management in Patients with IBD

Effective disease management in inflammatory bowel disease (IBD), which encompasses Crohn’s disease and ulcerative colitis, is incredibly important. Managing your condition helps you maintain a better quality-of-life, reduces uncomfortable or…

Continue Reading Physicians Identify Poor Disease Management in Patients with IBD
Can We Go Too Far with Self-Care?
source: shutterstock.com

Can We Go Too Far with Self-Care?

If you have read my books or articles, you have probably noticed that I talk about self-care quite a bit. I think self-care is extremely important for anyone, whether they…

Continue Reading Can We Go Too Far with Self-Care?
Encouraging Results from a Phase 2 Study of IL-2 to Treat Alzheimer’s Patients
kkolosov / Pixabay

Encouraging Results from a Phase 2 Study of IL-2 to Treat Alzheimer’s Patients

BioSpace recently published a press release discussing the interim results highlighting a Coya Therapeutics’ study. The study evaluates the safety, tolerability, and biological activity of LD IL-2 in 38 patients…

Continue Reading Encouraging Results from a Phase 2 Study of IL-2 to Treat Alzheimer’s Patients
New Podcast Episode: 50 Years of Supporting the TSC Community, feat. TSC Alliance President and CEO Kari Rosbeck
source: shutterstock.com

New Podcast Episode: 50 Years of Supporting the TSC Community, feat. TSC Alliance President and CEO Kari Rosbeck

Patient Worthy's award-winning podcast "Wait, How Do You Spell That? A Rare Disease Podcast" is back with a new episode. This week, Colby is sitting down with Kari Rosbeck, the…

Continue Reading New Podcast Episode: 50 Years of Supporting the TSC Community, feat. TSC Alliance President and CEO Kari Rosbeck
Enrollment Completed in Clinical Trials for Primary Sjögren’s Syndrome and IgA Nephropathy
source: shutterstock.com

Enrollment Completed in Clinical Trials for Primary Sjögren’s Syndrome and IgA Nephropathy

Jianmin Fang, M.D. the CEO of the biotechnology company RemeGen, recently announced in PRNewswire that the company is continuing its significant progress in its research of Telitacicept (RC18) to treat…

Continue Reading Enrollment Completed in Clinical Trials for Primary Sjögren’s Syndrome and IgA Nephropathy
First Patient Enrolled in VE303 Study for Recurrent C. Diff
source: shutterstock.com

First Patient Enrolled in VE303 Study for Recurrent C. Diff

An estimated 25% of people with Clostridioides difficile (C. diff) infections experience recurrence following successful antibiotic intervention. After three or more recurrent infections, the risk of developing another infection sits…

Continue Reading First Patient Enrolled in VE303 Study for Recurrent C. Diff
AGMB-447 Nabs Orphan Drug Designation as Potential IPF Treatment
https://pixabay.com/en/lungs-human-anatomy-bronchia-296392/

AGMB-447 Nabs Orphan Drug Designation as Potential IPF Treatment

People with idiopathic pulmonary fibrosis (IPF) already have two FDA-approved treatment options: Ofev (nintedanib) and Esbriet (pirfenidone). But biotech company Agomab Therapeutics ("Agomab") is working to introduce another potential therapeutic…

Continue Reading AGMB-447 Nabs Orphan Drug Designation as Potential IPF Treatment
Congressional Briefing Highlights Impact of Research Funding on Rare Eye Diseases: Retinitis Pigmentosa and Stargardt Disease
source: shutterstock.com

Congressional Briefing Highlights Impact of Research Funding on Rare Eye Diseases: Retinitis Pigmentosa and Stargardt Disease

Written by Judith Hill, Communications and Events Director, National Alliance for Eye and Vision Research In a remarkable show of unity and commitment to eye health, the Alliance for Eye…

Continue Reading Congressional Briefing Highlights Impact of Research Funding on Rare Eye Diseases: Retinitis Pigmentosa and Stargardt Disease

UC Davis Health Researchers Identify Biomarkers for Schizophrenia in 22q11.2 Deletion Syndrome

A 2008 report published in Current Psychiatry Reports found that approximately 1% of people with schizophrenia also have a rare genetic disorder called 22q11.2 deletion syndrome. This suggests that schizophrenia…

Continue Reading UC Davis Health Researchers Identify Biomarkers for Schizophrenia in 22q11.2 Deletion Syndrome
“An Event to End NF” Helped Teen Raise Funds, Awareness for Neurofibromatosis
https://pixabay.com/en/balloons-party-colors-rubber-fly-1786430/

“An Event to End NF” Helped Teen Raise Funds, Awareness for Neurofibromatosis

On May 17, 2024, Ohio was graced with a unique, Wizard of Oz-themed fundraising event called "An Event to End NF." NF, in this case, stands for neurofibromatosis, a rare genetic…

Continue Reading “An Event to End NF” Helped Teen Raise Funds, Awareness for Neurofibromatosis
Phase 3 Results: Imsidolimab Provides Positive Outlook in Generalized Pustular Psoriasis (GPP)
source: shutterstock.com

Phase 3 Results: Imsidolimab Provides Positive Outlook in Generalized Pustular Psoriasis (GPP)

Just about one month ago, clinical-stage biotechnology company AnaptysBio announced the availability of positive top-line results from two Phase 3 clinical studies: GEMINI-1 and GEMINI-2. Both studies sought to assess…

Continue Reading Phase 3 Results: Imsidolimab Provides Positive Outlook in Generalized Pustular Psoriasis (GPP)
Women More Likely to Develop De Novo Conditions Within One Year of Cushing Syndrome Remission
FotoshopTofs / Pixabay

Women More Likely to Develop De Novo Conditions Within One Year of Cushing Syndrome Remission

Researchers recently linked Cushing syndrome remission to the development of de novo (first occurrence) diseases, including autoimmune diseases, in various patients. But how did they reach this point? The first…

Continue Reading Women More Likely to Develop De Novo Conditions Within One Year of Cushing Syndrome Remission